Artykuły w czasopismach na temat „Equity lines”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Equity lines”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
ANNAOUI, Ilias, i Pascal BARNETO. "The Determinants of Equity Lines Financing: An International Study". Bankers, Markets & Investors 171, nr 3 (22.12.2022): 43–50. http://dx.doi.org/10.54695/bmi.171.8461.
Pełny tekst źródłaEbens, Allen J., Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby i in. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity". Blood 116, nr 21 (19.11.2010): 3001. http://dx.doi.org/10.1182/blood.v116.21.3001.3001.
Pełny tekst źródłaAnnaoui, Ilias, i Pascal Barneto. "Mécanismes de gouvernance et financement par Equity lines". Management & Avenir N° 135, nr 3 (6.06.2023): 37–60. http://dx.doi.org/10.3917/mav.135.0037.
Pełny tekst źródłaNgo, Anh, Oscar Varela i Xie Feixue. "The effects of lines of credit on market timing and the underpricing of seasoned equity offerings". Review of Accounting and Finance 18, nr 1 (11.02.2019): 157–75. http://dx.doi.org/10.1108/raf-09-2016-0153.
Pełny tekst źródłaThomenius, Michael J., Jennifer Totman, Kat Cosmopoulos, Dorothy Brach, Lei Ci, Neil Farrow, Jesse J. Smith i in. "Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation". Blood 132, Supplement 1 (29.11.2018): 3207. http://dx.doi.org/10.1182/blood-2018-99-110803.
Pełny tekst źródłaMunugalavadla, Veerendra, Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby i in. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies". Blood 116, nr 21 (19.11.2010): 4084. http://dx.doi.org/10.1182/blood.v116.21.4084.4084.
Pełny tekst źródłaDornan, David, Bart Burington, Peng Yue, Xiaoyan Shi, Ranjana Advani, Nancy Yu, Jeffrey T. Lau i in. "CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma." Blood 114, nr 22 (20.11.2009): 2721. http://dx.doi.org/10.1182/blood.v114.22.2721.2721.
Pełny tekst źródłaSALANDRO, DAN, i WILLIAM B. HARRISON. "Determinants of the Demand for Home Equity Credit Lines". Journal of Consumer Affairs 31, nr 2 (grudzień 1997): 326–45. http://dx.doi.org/10.1111/j.1745-6606.1997.tb00394.x.
Pełny tekst źródłaLiu, Yang, i J. Jimmy Yang. "Private debt, unused credit lines, and seasoned equity offerings". Quarterly Review of Economics and Finance 51, nr 4 (listopad 2011): 376–88. http://dx.doi.org/10.1016/j.qref.2011.07.006.
Pełny tekst źródłaNadelson, Louis S., Rachelle G. Miller, Helen Hu, Na Mi Bang i Brandy Walthall. "Is Equity on Their Mind? Documenting Teachers’ Education Equity Mindset". World Journal of Education 9, nr 5 (17.10.2019): 26. http://dx.doi.org/10.5430/wje.v9n5p26.
Pełny tekst źródłaEastman, Stephen, Christopher Shelton, Ira Gupta, Julie Krueger, Christina Blackwell i Paul M. Bojczuk. "Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines". Blood 134, Supplement_1 (13.11.2019): 4401. http://dx.doi.org/10.1182/blood-2019-123705.
Pełny tekst źródłaUlanet, Danielle, Victor Chubukov, John Coco, Gabrielle McDonald, Mya Steadman, Rohini Narayanaswamy, Sebastien Ronseaux i in. "Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials". Blood 134, Supplement_1 (13.11.2019): 1570. http://dx.doi.org/10.1182/blood-2019-123471.
Pełny tekst źródłaSampath, Deepak, Elizabeth Punnoose, Erwin R. Boghaert, Lisa Belmont, Jun Chen, Franklin Peale, Nguyen Tan i in. "Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models". Blood 120, nr 21 (16.11.2012): 5028. http://dx.doi.org/10.1182/blood.v120.21.5028.5028.
Pełny tekst źródłaErickson-Miller, Connie L., Jennifer Kirchner, Kodandaram Pillarisetti, Lone Ottesen, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin i Conrad Messam. "Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines." Blood 114, nr 22 (20.11.2009): 2409. http://dx.doi.org/10.1182/blood.v114.22.2409.2409.
Pełny tekst źródłaPramanik, Anik, Pan Xu i Yifan Xu. "Equity Promotion in Public Transportation". Proceedings of the AAAI Conference on Artificial Intelligence 37, nr 10 (26.06.2023): 11890–98. http://dx.doi.org/10.1609/aaai.v37i10.26403.
Pełny tekst źródłaMaira Muniz Almeida, Wanda, i Eliane Guaraldo. "Urban Green Equity". Life Style 8, nr 2 (2.06.2022): 64–74. http://dx.doi.org/10.19141/2237-3756.lifestyle.v8.n2.p64-74.
Pełny tekst źródłaPrabhu, Varun V., Rohinton S. Tarapore, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Jessica M. Wagner, Wafik S. El-Deiry, Martin Stogniew, Wolfgang Oster i Joshua E. Allen. "Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds". Blood 128, nr 22 (2.12.2016): 5133. http://dx.doi.org/10.1182/blood.v128.22.5133.5133.
Pełny tekst źródłaThakurta, Anjan, Anita K. Gandhi, Michelle Waldman, Chad C. Bjorklund, Suzanne Lentzsch, Stephen A. Schey, Yolanda Calle i in. "Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance". Blood 122, nr 21 (15.11.2013): 3139. http://dx.doi.org/10.1182/blood.v122.21.3139.3139.
Pełny tekst źródłaArora, Shilpi, Kaylyn Williamson, Shruti Apte, Srividya Balachander, Jennifer Busby, Charlie Hatton, Barbara Bryant i Patrick Trojer. "EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics". Blood 128, nr 22 (2.12.2016): 5672. http://dx.doi.org/10.1182/blood.v128.22.5672.5672.
Pełny tekst źródłaWang, Xiaomin, i Wenxin Zhang. "Efficiency and Spatial Equity Impacts of High-Speed Rail on the Central Plains Economic Region of China". Sustainability 11, nr 9 (5.05.2019): 2583. http://dx.doi.org/10.3390/su11092583.
Pełny tekst źródłaAhsan, Aarif, Ann Polonskaia, Chih-Chao Hsu, Chad C. Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis i in. "Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination". Blood 138, Supplement 1 (5.11.2021): 2658. http://dx.doi.org/10.1182/blood-2021-150641.
Pełny tekst źródłaChen, Janice, Christopher L. Brooks, Peter McDonald, Jonathan D. Schwartz, Rebecca S. Schneider, Keiichi Sakakibara, Naoya Saito, Takuji Sato, Takumi Kawabe i Eric K. Rowinsky. "SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity". Blood 126, nr 23 (3.12.2015): 4433. http://dx.doi.org/10.1182/blood.v126.23.4433.4433.
Pełny tekst źródłaLiu, Yang. "The Sources of Debt Matter Too". Journal of Financial and Quantitative Analysis 41, nr 2 (czerwiec 2006): 295–316. http://dx.doi.org/10.1017/s0022109000002076.
Pełny tekst źródłaPeng, Mao Yu, Yasmin Abaza, Martina Mcdermott, Monica Mead, Dennis J. Slamon i Sarah Larson. "Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations". Blood 136, Supplement 1 (5.11.2020): 6–7. http://dx.doi.org/10.1182/blood-2020-141459.
Pełny tekst źródłaZhang, Yue, Julie Parmentier, Zhongwu Lai, Greg O'Connor, Melissa Passino, Francoise Powell, Erik Devereaux i Kate Byth. "Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma". Blood 120, nr 21 (16.11.2012): 3720. http://dx.doi.org/10.1182/blood.v120.21.3720.3720.
Pełny tekst źródłaFernández, Leonor, i Peter Shorett. "Lessons in Equity From the Front Lines of COVID-19 Vaccination". JAMA Health Forum 2, nr 4 (7.04.2021): e210612. http://dx.doi.org/10.1001/jamahealthforum.2021.0612.
Pełny tekst źródłaTurner, PG. "Fault Lines In Equity Edited by Jamie Glister and Pauline Ridge". Oxford University Commonwealth Law Journal 12, nr 2 (27.03.2012): 393–97. http://dx.doi.org/10.1080/14729342.2012.11421351.
Pełny tekst źródłaGandhi, Anita K., Herve Avet-Loiseau, Michelle Waldman, Anjan Thakurta, Sharon L. Aukerman, Gengxin Chen, Derek Mendy i in. "Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells". Blood 120, nr 21 (16.11.2012): 4043. http://dx.doi.org/10.1182/blood.v120.21.4043.4043.
Pełny tekst źródłaLopez-Girona, Antonia, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka i in. "CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells". Blood 134, Supplement_1 (13.11.2019): 1812. http://dx.doi.org/10.1182/blood-2019-124338.
Pełny tekst źródłaLyons, Torrey, i Dong-ah Choi. "Transit Economic Equity Index: Developing a Comprehensive Measure of Transit Service Equity". Transportation Research Record: Journal of the Transportation Research Board 2675, nr 3 (7.01.2021): 288–300. http://dx.doi.org/10.1177/0361198120970529.
Pełny tekst źródłaRivera, Victor M., Justin R. Pritchard, Francois Gonzalvez, Theresa Baker, Joseph M. Gozgit i Graeme Hodgson. "Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events". Blood 124, nr 21 (6.12.2014): 1783. http://dx.doi.org/10.1182/blood.v124.21.1783.1783.
Pełny tekst źródłaLi, Lingna, Wenyong Tong, Megan Lau, Katherine Fells, Tong Zhu, Yingqing Sun, Ernest Kovacs i in. "Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies". Blood 134, Supplement_1 (13.11.2019): 5621. http://dx.doi.org/10.1182/blood-2019-132062.
Pełny tekst źródłaWang, Beatrice T., Thomas J. Matthew, Ling Wang, Tasnim Kothambawala, Susan E. Calhoun, Eric W. Humke, Angus M. Sinclair i Bruce A. Keyt. "The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML". Blood 136, Supplement 1 (5.11.2020): 43–44. http://dx.doi.org/10.1182/blood-2020-141449.
Pełny tekst źródłaBates, Jamie, Saritha Kusam, Stacey Tannheimer, Astrid Clarke, Thomas Kenney, David Breckenridge i Daniel Tumas. "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines". Blood 128, nr 22 (2.12.2016): 5104. http://dx.doi.org/10.1182/blood.v128.22.5104.5104.
Pełny tekst źródłaCojocari, Dan, Sha Jin, Julie J. Purkal, Relja Popovic, Nari N. Talaty, Yu Xiao, Larry R. Solomon, Erwin Boghaert, Joel D. Leverson i Darren C. Phillips. "5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis". Blood 132, Supplement 1 (29.11.2018): 2644. http://dx.doi.org/10.1182/blood-2018-99-111985.
Pełny tekst źródłaPinho, Pedro, Helen Kylefjord, Vilma Rraklli, Christina Rydergård, Biljana Rizoska, Anders Eneroth, Johan Bylund i in. "Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia". Blood 132, Supplement 1 (29.11.2018): 3497. http://dx.doi.org/10.1182/blood-2018-99-114440.
Pełny tekst źródłaKlatt, Martin G., Zhiyuan Yang, Jianying Liu, Tatyana Korontsvit, Sung Soo Mun, Leila Peraro, Thomas J. Gardner i in. "A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies". Blood 136, Supplement 1 (5.11.2020): 20–21. http://dx.doi.org/10.1182/blood-2020-140179.
Pełny tekst źródłaTotman, Jennifer, Dorothy Brach, Vinny Motwani, Selene Howe, Emily Deutschman, John Lampe, Thomas V. Riera i in. "Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma". Blood 138, Supplement 1 (5.11.2021): 1142. http://dx.doi.org/10.1182/blood-2021-151147.
Pełny tekst źródłaCheung, Kam, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy i in. "AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo". Blood 122, nr 21 (15.11.2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.
Pełny tekst źródłaChen, Jun, Sha Jin, Paul Tapang, Stephen K. Tahir, Morey Smith, John Xue, Haichao Zhang i in. "CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1". Blood 124, nr 21 (6.12.2014): 2161. http://dx.doi.org/10.1182/blood.v124.21.2161.2161.
Pełny tekst źródłaPenebre, Elayne, Kristy G. Kuplast, Christina R. Majer, L. Danielle Johnston, Nathalie Rioux, Michael Munchhof, Lei Jin i in. "Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma". Blood 124, nr 21 (6.12.2014): 438. http://dx.doi.org/10.1182/blood.v124.21.438.438.
Pełny tekst źródłaWeyland, Kurt. "“Growth With Equity” in Chile's New Democracy?" Latin American Research Review 32, nr 1 (1997): 37–68. http://dx.doi.org/10.1017/s0023879100037651.
Pełny tekst źródłaRychak, Emily, Derek Mendy, Karen Miller, Jim Leisten, Rama Krishna Narla, Heather K. Raymon, Rajesh Chopra i Antonia Lopez-Girona. "The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide". Blood 122, nr 21 (15.11.2013): 3160. http://dx.doi.org/10.1182/blood.v122.21.3160.3160.
Pełny tekst źródłaMcElligott, David L., Edward Kesicki, Kannan Karukarichi, Hyeseok Shim, Rui Wang, Albert S. Yu, Parisa Zolfaghari i in. "Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies". Blood 132, Supplement 1 (29.11.2018): 213. http://dx.doi.org/10.1182/blood-2018-99-118355.
Pełny tekst źródłaCsibi, Fred, Nan Ji, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, Scott Rusin i in. "Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies". Blood 134, Supplement_1 (13.11.2019): 3803. http://dx.doi.org/10.1182/blood-2019-128981.
Pełny tekst źródłaDing, Bei Bei, John Dixon Gray, Irina Krapf, Yanliang Zhang, Nan Zhang, Qingdong Mark Deng, Angel Wei i in. "Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure". Blood 134, Supplement_1 (13.11.2019): 4444. http://dx.doi.org/10.1182/blood-2019-131586.
Pełny tekst źródłaFiore, Christopher, Michael R. McKeown, Emily Lee, Matthew L. Eaton i Christian C. Fritz. "SY1425 (tamibarotene) Induces Profound Transcriptional Changes in AML Tumors with High Retinoic Acid Receptor Alpha". Blood 128, nr 22 (2.12.2016): 1523. http://dx.doi.org/10.1182/blood.v128.22.1523.1523.
Pełny tekst źródłaLowe, Eric, Andrea R. Fan, Jing Jiang, Henry W. B. Johnson, Christopher J. Kirk, Dustin McMinn, Tony Muchamuel, Yu Qian i Brian B. Tuch. "Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies". Blood 134, Supplement_1 (13.11.2019): 408. http://dx.doi.org/10.1182/blood-2019-123782.
Pełny tekst źródłaYang, Jun, Andong Guo, Xueming Li i Tai Huang. "Study of the Impact of a High-Speed Railway Opening on China’s Accessibility Pattern and Spatial Equality". Sustainability 10, nr 8 (19.08.2018): 2943. http://dx.doi.org/10.3390/su10082943.
Pełny tekst źródłaAryal, Neeraj K., Anjana Sundarrajan, Scott Boiko, David Jenkins, Huayang Liu, Miika Ahdesmaki, Aurelie Bornot i in. "Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma". Blood 138, Supplement 1 (5.11.2021): 2275. http://dx.doi.org/10.1182/blood-2021-151194.
Pełny tekst źródła